Sympathetic nerve activity is inappropriately increased in chronic renal disease.

The hypothesis that in hypertensive patients with renal parenchymal disease sympathetic activity is "inappropriately" elevated and that this overactivity is a feature of renal disease and not of a reduced number of nephrons per se is addressed. Fifty seven patients with renal disease (various causes, no diabetes, all on antihypertensive medication) were studied, age range 18 to 62, creatinine clearance 10 to 114 ml/min per 1.73 m(2). Antihypertensives were stopped, but diuretics were allowed, to prevent overhydration. Matched control subjects were also studied. The effect of changes in fluid status was examined in seven patients while on and after stopping diuretics and in eight control subjects while on low- and high-sodium diet. Seven kidney donors were studied before and after unilateral nephrectomy. Sympathetic activity was quantified as muscle sympathetic nerve activity (MSNA) in the peroneal nerve. Mean arterial pressure, MSNA, and plasma renin activity were higher in patients than in control subjects, respectively (115 +/- 12 and 88 +/- 11 mmHg, 31 +/- 15 and 18 +/- 10 bursts/min, and 500 [20 to 6940] and 220 [40 to 980] fmol/L per s; P < 0.01 for all items). Extracellular fluid volume (bromide distribution) did not differ. Seven patients were studied again after stopping diuretics. MSNA decreased from 34 +/- 18 to 19 +/- 18 bursts/min (P < 0.01). Eight healthy subjects were studied during low- and high-sodium diet. MSNA was 26 +/- 12 and 13 +/- 7 bursts/min (P < 0.01). The curves relating extracellular fluid volume to MSNA were parallel in the two groups but shifted to a higher level of MSNA in the patients. In the kidney donors, creatinine clearance reduced by 25%, but MSNA was identical before and after donation. It is concluded that in hypertensive patients with renal parenchymal disease, sympathetic activity is inappropriately high for the volume status and that reduction of nephron number in itself does not influence sympathetic activity.

[1]  O. Tochikubo,et al.  Muscle Sympathetic Nerve Activity in Renovascular Hypertension and Primary Aldosteronism , 1991, Hypertension.

[2]  P. Blankestijn,et al.  Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. , 2003, Journal of the American Society of Nephrology : JASN.

[3]  J. Roos,et al.  Renal sodium handling in normal humans subjected to low, normal, and extremely high sodium supplies. , 1985, The American journal of physiology.

[4]  R. Converse,et al.  Sympathetic overactivity in patients with chronic renal failure. , 1992, The New England journal of medicine.

[5]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  C. Zoccali,et al.  Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease , 2002, Circulation.

[7]  P. Blankestijn,et al.  Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. , 2001, Journal of the American Society of Nephrology : JASN.

[8]  G. Mancia,et al.  Short- and Long-Term Neuroadrenergic Effects of Moderate Dietary Sodium Restriction in Essential Hypertension , 2002, Circulation.

[9]  G. Mancia,et al.  Baroreflex impairment by low sodium diet in mild or moderate essential hypertension. , 1997, Hypertension.

[10]  I. Reid.  Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. , 1992, The American journal of physiology.

[11]  M. Pfeffer,et al.  Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  V. Campese,et al.  Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. , 1997, Kidney international.

[13]  K. Rahn,et al.  Sympathetic Nerve Activity in End-Stage Renal Disease , 2002, Circulation.

[14]  K H Wesseling,et al.  The reliability of noninvasive continuous finger blood pressure measurement in patients with both hypertension and vascular disease. , 1992, American journal of hypertension.

[15]  M. Brody,et al.  Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. , 1985, Circulation research.

[16]  K Doqi,et al.  clinical practice guidelines for chronic kidney disease : evaluation, classification, and stratification , 2002 .

[17]  J. Brown,et al.  Hypertension in chronic renal failure. An abnormal relation between sodium and the renin-angiotensin system. , 1973, The American journal of medicine.

[18]  B. Wallin,et al.  A Quantitative Study of Muscle Nerve Sympathetic Activity in Resting Normotensive and Hypertensive Subjects , 1979, Hypertension.

[19]  P. Boer.  Estimated lean body mass as an index for normalization of body fluid volumes in humans. , 1984, The American journal of physiology.

[20]  Hirofumi Tanaka,et al.  Influence of age on arterial baroreflex inhibition of sympathetic nerve activity in healthy adult humans. , 1998, American journal of physiology. Heart and circulatory physiology.

[21]  G. Grassi,et al.  Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. , 1995, Circulation.

[22]  P. Blankestijn,et al.  Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. , 1999, The New England journal of medicine.

[23]  M. Zonderland,et al.  Direct assessment of extracellular water volume by the bromide‐dilution method in growth hormone‐deficient adults* , 1995, European journal of clinical investigation.

[24]  J. J. Smith,et al.  Effects of aging on baroreflex regulation of sympathetic activity in humans. , 1992, The American journal of physiology.

[25]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.